Chrysamine G and its derivative reduce amyloid β-induced neurotoxicity in mice

Neuroscience Letters

Volumn 333, Issue 1, 2002, Pages 5-8

  Ishii, Kazuhiro ^a   Klunk, William E ^b   Arawaka, Shigeki ^c   Debnath, Manik L ^d   Furiya, Yoshiko ^a   Sahara, Naruhiko ^a   Shoji, Shin'ichi ^a   Tamaoka, Akira ^a   Pettegrew, Jay W ^a   Mori, Hiroshi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid 1 40; Amyloid 25 35; Chrysamine G; Half chrysamine G; Neurotoxicity

Indexed keywords

AMYLOID BETA PROTEIN; CARBOXYLIC ACID DERIVATIVE; CHRYSAMINE G; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BRAIN NERVE CELL; CONTROLLED STUDY; EMBRYO; HUMAN; MOUSE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

AMYLOID BETA-PROTEIN; ANIMALS; BENZOATES; BIPHENYL COMPOUNDS; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; EMBRYO; HUMANS; MICE; MICE, INBRED ICR; PEPTIDE FRAGMENTS;

EID: 0037110932     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(02)00915-1     Document Type: Article

References (21)

1. Behl C., Davis J.B., Cole G.M., Schubert D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem. Biophys. Res. Commun. 186:1992;944-950.
2. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
3. Frautschy S.A., Baird A., Cole G.M. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc. Natl. Acad. Sci. USA. 88:1991;8362-8366.
4. Gearing M., Mori H., Mirra S.S. Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann. Neurol. 39:1996;395-399.
5. Ishii K., Tamaoka A., Mizusawa H., Shoji S., Ohtake T., Fraser P.E., Takahashi H., Tsuji S., Gearing M., Mizutani T., Yamada S., Kato M., St George-Hyslop P.H., Mirra S.S., Mori H. Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. Brain Res. 748:1997;250-252.
6. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 13:1994;45-53.
7. Jarrett J.T., Lansbury P.T. Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 73:1993;1055-1058.
8. Kaneko I., Yamada N., Sakuraba Y., Kamenosono M., Tutumi S. Suppression of mitochondrial succinate dehydrogenase, a primary target of beta-amyloid, and its derivative racemized at Ser residue. J. Neurochem. 65:1995;2585-2593.
9. Klunk W.E., Debnath M.L., Pettegrew J.W. Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol. Aging. 15:1994;691-698.
10. Klunk W.E., Debnath M.L., Pettegrew J.W. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol. Aging. 16:1995;541-548.
11. Klunk W.E., Debnath M.L., Koros A.M., Pettegrew J.W. Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. Life Sci. 63:1998;1807-1814.
12. Liu Y., Peterson D.A., Kimura H., Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J. Neurochem. 69:1997;581-593.
13. Manelli A.M., Puttfarcken P.S. Beta-Amyloid-induced toxicity in rat hippocampal cells: in vitro evidence for the involvement of free radicals. Brain Res. Bull. 38:1995;569-576.
14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
15. Porter W.J., Audia J.E., Boggs L.N., Droste J.J., Fuson K.S., Hyslop P.A., Johnson T., May P.C. Correlation between inhibition of Aβ peptide (1-40) neurotoxicity and fibril growth with a series of azo dye analogs. Amer. Chem. Soc. 215th National Mgt. Div. Chem. Abstr. 1998;212.
16. Prehn J.H., Bindokas V.P., Jordan J., Galindo M.F., Ghadge G.D., Roos R.P., Boise L.H., Thompson C.B., Krajewski S., Reed J.C., Miller R.J. Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons. Mol. Pharmacol. 49:1996;319-328.
17. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:1996;864-870.
18. Walter M.F., Klunk W.E., Giovanni A., Mason R.P., Chrysamine G. inhibits lipid peroxidation and the insertion of amyloid β into model membranes. Soc. Neurosci. Abstr. 23:1997;1663.
19. Wirtz-Brugger F., Givanni A. Amyloid-induced andd NGF withdrawal-induced neuronal death in differentiated PC12 cells: common mechanism? Soc. Neurosci. Abstr. 23:1997;1627.
20. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 382:1996;685-691.
21. Yankner B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 250:1990;279-282.